table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
COVID 19 hospitalizedCOVID-19 mild to moderateCOVID-19 severe or critically
Kinase inhibitors
acalabrutinib CALAVI US CALAVI
imatinib Covid-19 HUF Aman

1 studies excluded by filtering options 3

6323 Roschewski, 2020 2990excludednot a RCTrisk of bias not avaialble

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons